Small molecule inhibitors targeting m⁶A regulators.

Area of Science:

• Epigenetics
• RNA biology
• Cancer research

Background:

• N⁶ methyladenosine (m⁶A) is a prevalent RNA modification impacting growth, development, and DNA damage response.
• Aberrant m⁶A expression in cancer promotes tumor progression, affecting proliferation, metastasis, drug resistance, immunity, and prognosis.
• m⁶A's role in cancer has led to the development of small molecules targeting m⁶A regulators for anti-tumor therapies.

Purpose of the Study:

• To comprehensively review m⁶A regulators, their functions, and interactions with cancer hallmarks.
• To provide an overview of small molecules targeting m⁶A regulators for cancer treatment, including their development, mechanism of action, pharmacology, and structure-activity relationships.
• To offer insights for future drug design and optimization in targeting m⁶A for cancer therapy.

Main Methods:

• Literature review and synthesis of existing research on m⁶A regulators and small molecule inhibitors.
• Analysis of m⁶A regulator functions in cancer proliferation, metastasis, drug resistance, and immune responses.
• Compilation and discussion of data on the development, pharmacology, and structure-activity relationships of small molecules targeting m⁶A regulators.

Main Results:

• m⁶A regulators play critical roles in various cancers, influencing tumor cell behavior and patient outcomes.
• Small molecules targeting m⁶A regulators demonstrate potential for precise intervention in RNA modifications.
• These small molecules disrupt tumor cell survival mechanisms, offering novel anti-cancer therapeutic avenues.

Conclusions:

• m⁶A modification is a significant factor in cancer biology, presenting therapeutic opportunities.
• Small molecules targeting m⁶A regulators are promising agents for novel cancer treatments.
• Further research into small molecule development targeting m⁶A regulators is warranted for optimized drug design and future clinical applications.